Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB11 | A5LHX3 | 9/20 | 0.65 |
| ▸ | PSMA7 | O14818 | 9/20 | 0.65 |
| ▸ | PSMB1 | P20618 | 9/20 | 0.65 |
| ▸ | PSMA1 | P25786 | 9/20 | 0.65 |
| ▸ | PSMA2 | P25787 | 9/20 | 0.65 |
| ▸ | PSMA3 | P25788 | 9/20 | 0.65 |
| ▸ | PSMA4 | P25789 | 9/20 | 0.65 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.65 |
| ▸ | PSMB9 | P28065 | 9/20 | 0.65 |
| ▸ | PSMA5 | P28066 | 9/20 | 0.65 |
| ▸ | PSMB4 | P28070 | 9/20 | 0.65 |
| ▸ | PSMB6 | P28072 | 9/20 | 0.65 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.65 |
| ▸ | PSMB10 | P40306 | 9/20 | 0.65 |
| ▸ | PSMB3 | P49720 | 9/20 | 0.65 |
| ▸ | PSMB2 | P49721 | 9/20 | 0.65 |
| ▸ | PSMA6 | P60900 | 9/20 | 0.65 |
| ▸ | PSMA8 | Q8TAA3 | 9/20 | 0.65 |
| ▸ | PSMB7 | Q99436 | 9/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17514303 | 0.95 | GAA (0.61) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL18396386 | 0.91 | PSMB5 (0.62) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL18395891 | 0.91 | PSMB5 (0.66) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL18395122 | 0.89 | PSMB11 (0.63) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL18396363 | 0.89 | PSMB5 (0.63) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL18395045 | 0.88 | PSMB5 (0.64) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL18394616 | 0.84 | PSMB5 (0.66) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL18395884 | 0.83 | RAB9A (0.58) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL17514304 | 0.83 | HTT (0.54) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL18395980 | 0.82 | PSMB5 (0.64) | PSMB11PSMA7PSMB1PSMA1PSMA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3127912-B1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | UNIV ZHEJIANG (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-9856288-B2 | Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof | ZHEJIANG UNIVERSITY (CN) | 2018-01-02 | — | — | US | disclosed |
| EP-3127912-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | Zhejiang University (CN) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022250-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA , CHINESE ACADEMY OF SCIENCES (CN) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022250-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | VIP, DNPEP, PREP | PSMB11 492/4885PSMA7 332/4885PSMB1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.